Critical Care Nutrition: Systematic Reviews December 2018

4.2c Composition of Enteral Nutrition: High Protein vs. Low Protein

Question: Compared to a lower enteral protein intake does a higher protein intake enteral formula result in better outcomes in the critically ill adult patient?

Summary of evidence: There were 3 level 2 studies that compared the effect of a higher protein regimen to a lower protein regimen. Clifton (1985) compared the high-protein formula Traumacal to the lower protein formula Magnacal in head injured patients. Rugeles (2014) compared a hypocaloric hyperprotein regimen to a standard regimen. Fetterplace (2018) compared the high protein formula Nutrison Protein Plus to the lower protein formula Nutrison in medical and surgical ICU patients. Scheinkestel (2003) was excluded from this review because the average protein goals of the two groups did not differ (the control group's protein goal was 2 g/kg/d vs the intervention group's protein goal was 1.5 g/kg/d x 2 days, 2.0 g/kg/d x 2 days and 2.5 g/kg/d x 2 days).

Mortality: All three studies reported on mortality, though at different time intervals. Overall, there was no effect on mortality (RR 0.89, 95% CI 0.50, 1.60, p=0.70, l² heterogeneity=0%; figure 1).

Infections: In the study that reported on infections (Clifton, 1985), there were more bacterial infections in the group receiving the higher protein formula but this was not statistically significant (RR 1.50, 95 % Cl 0.32, 7.1).

LOS and Ventilator days: Two studies reported on these outcomes (Rugeles 2014, Fetterplace 2018) and there was no significant difference on ICU LOS (WMD -0.94, 95% CI -2.75, 0.87, p=0.31, I² heterogeneity=0%; figure 2), hospital LOS (WMD 3.05, 95% CI -6.24, 12.35, p=0.52, I² heterogeneity=81%; figure 3) or length of mechanical ventilation (WMD -0.02, 95% CI -2.81, 2.77, p=0.99, I² heterogeneity=54%; figure 4).

Physical Outcomes: Fetterplace 2018 was the only study that reported on physical outcomes. They found no difference between groups with regards to hand grip strength, muscle strength (Medical Research Council (MRC) scale), ICU acquired weakness (MRC < 48), and physical function (Physical Function in Intensive Care Unit Test (PFIT-s)).

Other: In the study by Clifton (1985), nitrogen balance was higher in the higher protein group but this was not statistically significant. Rugeles 2014 showed no difference in calories received but a significant difference in protein received (1.4 g/kg/d vs 0.76 g/kg/d, p \leq 0.0001). Fetterplace 2018 showed significantly higher calories and protein received in the high protein group (84% vs 73% caloric adequacy, p=0.01 and 90% vs 57% protein adequacy, p<0.001). Time to start EN was significantly shorter in the high protein group (13 vs 20 hours, p=0.01). In the high vs low protein groups, there were no differences in diarrhea occurrence (16/30 patients in both groups, p=1.0) and feeding intolerance (30% vs 27%, p=0.77). No difference

was found in the physical outcomes tested, except in quadriceps muscle layer thickness (QMLT) assessed by ultrasound at baseline and ICU discharge. The intervention was associated with less QMLT loss at discharge, with an average attenuated loss of 0.22 cm (95% CI 0.06, 0.38, p=0.01; table 2).

Conclusions:

- 1) A higher protein formula has no effect on mortality in critically ill patients.
- 2) A higher protein formula has no effect on infectious complications in critically ill head injured patients.
- 3) A higher protein formula has no effect on ICU length of stay, hospital length of stay or duration of mechanical ventilation in critically ill patients.

Level 1 study: if all of the following are fulfilled: concealed randomization, blinded outcome adjudication and an intention to treat analysis. Level 2 study: If any one of the above characteristics are unfulfilled.

Study	Population	Methods (score)	Intervention	Mortalit High protein	ty # (%) Low Protein	RR (CI)**	Infection High protein	ns # (%) Low Protein	RR (CI)**
1) Clifton 1985	Head injured patients Comatose for 24 hrs N=20	C.Random: not sure ITT: yes Blinding: no (8)	22% pro, 38 % CHO, 41 % fat, 1.5 Kcal/ml (Traumacal) vs. 14 % pro, 50 % CHO, 36 % fat, 2.0 Kcal/ml (Magnacal) Isocaloric, 29 gm Nitrogen vs.17.6 gms Nitrogen	3 Month 1/10 (10)	3 Month 1/10 (10)	1.00 (0.07-13.9)	3/10 (30)	2/10 (20)	1.50 (0.32, 7.1)
3) Rugeles 2013	Medical adult ICU patients N=80	C.Random: yes ITT: no Blinding: double (7)	hypocaloric hyperproteic (15 kcal/kg, 1.7 g/kg/d) x 7 days vs standard (25 kcal/kg, 20% calories from protein).	28 day 11/40	28 day 12/40		NR	NR	NA
4) Fetterplace 2018	Medical and surgical ICU patients. Single centre. N=60	C.Random: yes ITT: yes Blinding: single (10)	1.5 g/kg/d x 15 days from high protein EN (Nutrison Protein Plus) vs 1.0 g/kg/d from standard EN (Nutrison)	28 day 4/30 60 day 4/30	28 day 5/30 60 day 5/30		NR	NR	NA

Table 1. Randomized Studies Evaluating Higher Protein vs. Low Protein Enteral Formula in Critically ill Patients

C.Random: concealed randomization

 \pm : mean \pm standard deviation

Church	Machanical Vantilation	1.00	
Sludy		LUS	Nutrition parameters
	High protein Low Protein	High protein Low Protein	High protein Low Protein
1) Clifton 1985	NR	NR	Calories (kcal/kg/d) 51 48 Grams nitrogen/day 0.42 0.24
2) Rugeles 2013	8.5 <u>+</u> 4.6 days (40) 9.7 <u>+</u> 4.9 days (40)	ICU 9.5 <u>+</u> 5.5 days 10.4 <u>+</u> 5.0 days Hospital 19.5 <u>+</u> 6.5 days 20.5 <u>+</u> 5 days	Calories (kcal/kg/d) 12 14 Protein (g/kg/d) 1.4 0.76
3) Fetterplace 2018	8.7 <u>+</u> 7.5 days (30) 7.0 <u>+</u> 5.0 days (30)	ICU 10.6 <u>+</u> 8.3 days 9.1 <u>+</u> 5.5 days Hospital 27.4 <u>+</u> 19.0 days 18.8 <u>+</u> 10.9 days	Calories (kcal/kg/d) 21 ± 5.2 18 ± 2.7 , p=0.01Protein (g/kg/d) 1.2 ± 0.3 0.75 ± 0.11 , p<0.001Caloric adequacy, % 84 ± 21 73 ± 11 , p=0.01Protein adequacy, % 90 ± 25 57 ± 8 , p<0.001Time to start EN (h) 13 ± 8 20 ± 10 , p=.01Diarrhea $16/30$ (53%) $16/30$ (53%), p=1.0Feeding intolerance $9/30$ (30) $8/30$ (27), p=0.77

Table 1. Randomized Studies Evaluating Higher Protein vs. Low Protein Enteral Formula in Critically ill Patients (continued)

ITT: intent to treat NR: Not reported

** RR= relative risk, CI= Confidence intervals

Table 2. Physical Outcomes

Study	Physical outcomes High protein Low Protein							
3) Fetterplace 2018	Handgrip strength, kg							
	20 (6.1), n=6 21 (9.3), n=16, p=0.94							
	Muscle strength (MRC score)							
	55 (5.9), n=7 52 (9.6), n=14, p=0.53							
	ICU acquired weakness (MRC<48)							
	1 (14), n=7 4 (28), n=14, p=0.47							
	Physical function in ICU test							
	6 8 (3 8), n=8 7 9 (3 4), n=14, n=0 49							
	Quadricep Muscle Laver Thickness (ultrasound)							
	Intervention: effect 0.22, 95% CI 0.06-0.038, p=0.01n=24 (intervention), n=23 (control)							

Figure 1. Mortality

	High D	ose	Low D	ose		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	Year	M-H, Random, 95% Cl
Clifton 1985	1	10	1	10	5.0%	1.00 [0.07, 13.87]	1985	· · · · · · · · · · · · · · · · · · ·
Rugeles 2013	11	40	12	40	71.8%	0.92 [0.46, 1.83]	2013	
Fetterplace 2018	4	30	5	30	23.3%	0.80 [0.24, 2.69]	2018	
Total (95% CI)		80		80	100.0%	0.89 [0.50, 1.60]		
Total events	16		18					
Heterogeneity: Tau ² =	0.00; Chi	i² = 0.04	4, df = 2 (P = 0.9	8); I ^z = 09	6		
Test for overall effect: Z = 0.38 (P = 0.70)								Favours high dose Favours low dose

Figure 2. ICU LOS

	High Dose Low Dose					e		Mean Difference		Mean Difference				
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year		IV, Rando	om, 95% Cl		
Rugeles 2013	9.5	5.5	40	10.4	5	40	61.9%	-0.90 [-3.20, 1.40]	2013					
Fetterplace 2018	19.5	6.5	30	20.5	5	30	38.1%	-1.00 [-3.93, 1.93]	2018			•		
Total (95% CI)			70			70	100.0%	-0.94 [-2.75, 0.87]				•		
Heterogeneity: Tau ² = 0.00; Chi ² = 0.00, df = 1 (P = 0.96); I ² = 0% Test for overall effect: Z = 1.01 (P = 0.31)							%			-100 -5 Favours [0	 50 experimental]	0 Favours [co	50 ontrol]	100

Figure 3. Hospital LOS

	High	h Dos	e	Lov	v Dos	е		Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI
Rugeles 2013	19.5	6.5	40	20.5	5	40	57.8%	-1.00 [-3.54, 1.54]	2013	
Fetterplace 2018	27.4	19	30	18.8	10.9	30	42.2%	8.60 [0.76, 16.44]	2018	
Total (95% CI)			70			70	100.0%	3.05 [-6.24, 12.35]		•
Heterogeneity: Tau ² = 37.24; Chi ² = 5.21, df = 1 (P = 0.02); l ² = 81										
Test for overall effect:	Z = 0.64	(P =	0.52)							Favours [experimental] Favours [control]

Figure 4. Duration of Ventilation

	High Dose Low				/ Dos	e		Mean Difference		Mean Difference			
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% Cl			
Rugeles 2013	8.5	4.6	40	9.7	4.9	40	59.4%	-1.20 [-3.28, 0.88]	2013	•			
Fetterplace 2018	8.7	7.5	30	7	5	30	40.6%	1.70 [-1.53, 4.93]	2018				
Total (95% CI)			70			70	100.0%	-0.02 [-2.81, 2.77]		+			
Heterogeneity: Tau ² = 2.29; Chi ² = 2.19, df = 1 (P = 0.14); l ² = 54%											1		
Test for overall effect: Z = 0.02 (P = 0.99)										Favours [experimental] Favours [control]	·		

Table 3. Excluded Articles

#	Reason excluded	Citation
1	No clinical outcomes	Twyman D, Young AB, Ott L, Norton JA, Bivins BA. High protein enteral feedings: a means of achieving positive nitrogen balance in head injured patients JPEN J Parenter Enteral Nutr. 1985 Nov-Dec;9(6):679-84.
2	Intervention delivered via PN only	Larsson J, Lennmarken C, Martensson J, Sandstedt S, Vinnars E. Nitrogen requirements in severely injured patients. Br J Surg 1990;77(4):413-6.
3	Intervention delivered via PN only	Pitkanen O, Takala J, Poyhonen M, Kari A. Nitrogen and energy balance in septic and injured intensive care patients: response to parenteral nutrition. Clin Nutr 1991;10(5):258-65.
4	Not high vs low protein - one group received 2/g/kg/d x 6 days. Other group received 1.5 g/kg/d x 2d, 2.0 g/kg/d x 2d, 2.5 g/kg/d x 2d.	Scheinkestel CD, Kar L, Marshall K, Bailey M, Davies A, Nyulasi I, Tuxen DV. Prospective randomized trial to assess caloric and protein needs of critically III, anuric, ventilated patients requiring continuous renal replacement therapy. Nutrition. 2003 Nov-Dec;19(11-12):909-16.
5	Stroke patients	ZHOU C, SU Y. Effect of the equal non-protein-calorie but different protein intake on enteral nutritional metabolism in 51 patients with severe stroke: A randomized controlled study [J]. Chinese Journal of Clinical Nutrition. 2006;6:004.
6	No clinical outcomes; intervention delivered via PN only	Singer P. High-dose amino acid infusion preserves diuresis and improves nitrogen balance in non-oliguric acute renal failure. Wien Klin Wochenschr 2007;119(7-8):218-22.

7	Not ICU patients	Botella-Carretero JI, Iglesias B, Balsa JA, Zamarron I, Arrieta F, Vazquez C. Effects of oral nutritional supplements in normally nourished or mildly undernourished geriatric patients after surgery for hip fracture: a randomized clinical trial. JPEN Journal of parenteral and enteral nutrition 2008;32(2):120-8.
8	Adolescent patients; intervention delivered via PN only	Verbruggen SC, Coss-Bu J, Wu M, Schierbeek H, Joosten KF, Dhar A, et al. Current recommended parenteral protein intakes do not support protein synthesis in critically ill septic, insulin-resistant adolescents with tight glucose control. Crit Care Med 2011;39(11):2518-25.
9	Not critically ill patients, not clinically significant outcomes	Tavenier J, Haupt TH, Andersen AL, Buhl SF, Langkilde A, Andersen JR, Jensen JB, Pedersen MM, Petersen J, Andersen O. A high- protein diet during hospitalization is associated with an accelerated decrease in soluble urokinase plasminogen activator receptor levels in acutely ill elderly medical patients with SIRS. Nutr Res. 2017 May;41:56-64.